1
|
Lenzuni M, Bonfadini S, Criante L, Zorzi F, Summa M, Bertorelli R, Suarato G, Athanassiou A. Dynamic investigation of zein-based degradable and hemocompatible coatings for drug-eluting stents: a microfluidic approach. LAB ON A CHIP 2023; 23:1576-1592. [PMID: 36688523 DOI: 10.1039/d3lc00012e] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Biodegradable stent coatings have shown great potential in terms of delivering drugs to a damaged vessel wall, and their release profiles are key elements governing the overall performance of drug-eluting stents (DESs). However, release and degradation kinetics are usually not tested under simulated physiological conditions or in dynamic environments, both essential aspects in the design of novel DESs. To bridge this gap, fused silica-based microfluidic systems, with either round or square channel cross-sections, were designed to mimic the microenvironment of a stented vessel. In particular, we fabricated and characterized microfluidic chips based on customizable channels, which were spray-coated with a naturally-derived, rutin-loaded zein solution, to perform a comprehensive study under flow conditions. Dynamic assays after 6 hours showed how the degradation of the zein matrix was affected by the cross-sectional conformation (∼69% vs. ∼61%, square and round channel, respectively) and the simulated blood fluid components (∼55%, round channel with a more viscous solution). The released amount of rutin was ∼81% vs. ∼77% and ∼78% vs. ∼74% from the square and round channels, using the less and more viscous blood-simulated fluids, respectively. Fitting the drug release data to Korsmeyer-Peppas and first-order mathematical models provided further insight into the mechanism of rutin release and coating behavior under flowing conditions. More importantly, whole blood tests with our newly developed microfluidic platforms confirmed the hemocompatibility of our zein-based coating. In detail, in-flow and static studies on the blood cell behavior showed a significant reduction of platelet adhesion (∼73%) and activation (∼93%) compared to the stainless-steel substrate, confirming the benefits of using such naturally-derived coatings to avoid clogging. Overall, our microfluidic designs can provide a key practical tool for assessing polymer degradation and drug release from degradable matrices under flowing conditions, thus aiding future studies on the development of hemocompatible, controlled-release coatings for DESs.
Collapse
Affiliation(s)
- Martina Lenzuni
- Smart Materials Group, Istituto Italiano di Tecnologia, via Morego 30, Genoa, Italy.
- Department of Computer Science, Bioengineering, Robotics and Systems Engineering, University of Genoa, via Opera Pia 13, Genoa, Italy
| | - Silvio Bonfadini
- Center for Nano Science and Technology @ PoliMi, Istituto Italiano di Tecnologia, via Pascoli 70/3, Milan, Italy
| | - Luigino Criante
- Center for Nano Science and Technology @ PoliMi, Istituto Italiano di Tecnologia, via Pascoli 70/3, Milan, Italy
| | - Filippo Zorzi
- Center for Nano Science and Technology @ PoliMi, Istituto Italiano di Tecnologia, via Pascoli 70/3, Milan, Italy
- Department of Physics, Politecnico di Milano, Piazza Leonardo da Vinci, 32, Milan, Italy
| | - Maria Summa
- Translational Pharmacology, Istituto Italiano di Tecnologia, via Morego 30, Genoa, Italy
| | - Rosalia Bertorelli
- Translational Pharmacology, Istituto Italiano di Tecnologia, via Morego 30, Genoa, Italy
| | - Giulia Suarato
- Smart Materials Group, Istituto Italiano di Tecnologia, via Morego 30, Genoa, Italy.
- Translational Pharmacology, Istituto Italiano di Tecnologia, via Morego 30, Genoa, Italy
| | | |
Collapse
|
3
|
Mahmoud AD, Ballantyne MD, Miscianinov V, Pinel K, Hung J, Scanlon JP, Iyinikkel J, Kaczynski J, Tavares AS, Bradshaw AC, Mills NL, Newby DE, Caporali A, Gould GW, George SJ, Ulitsky I, Sluimer JC, Rodor J, Baker AH. The Human-Specific and Smooth Muscle Cell-Enriched LncRNA SMILR Promotes Proliferation by Regulating Mitotic CENPF mRNA and Drives Cell-Cycle Progression Which Can Be Targeted to Limit Vascular Remodeling. Circ Res 2019; 125:535-551. [PMID: 31339449 PMCID: PMC6693924 DOI: 10.1161/circresaha.119.314876] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 07/05/2019] [Accepted: 07/19/2019] [Indexed: 12/20/2022]
Abstract
RATIONALE In response to blood vessel wall injury, aberrant proliferation of vascular smooth muscle cells (SMCs) causes pathological remodeling. However, the controlling mechanisms are not completely understood. OBJECTIVE We recently showed that the human long noncoding RNA, SMILR, promotes vascular SMCs proliferation by a hitherto unknown mechanism. Here, we assess the therapeutic potential of SMILR inhibition and detail the molecular mechanism of action. METHODS AND RESULTS We used deep RNA-sequencing of human saphenous vein SMCs stimulated with IL (interleukin)-1α and PDGF (platelet-derived growth factor)-BB with SMILR knockdown (siRNA) or overexpression (lentivirus), to identify SMILR-regulated genes. This revealed a SMILR-dependent network essential for cell cycle progression. In particular, we found using the fluorescent ubiquitination-based cell cycle indicator viral system that SMILR regulates the late mitotic phase of the cell cycle and cytokinesis with SMILR knockdown resulting in ≈10% increase in binucleated cells. SMILR pulldowns further revealed its potential molecular mechanism, which involves an interaction with the mRNA of the late mitotic protein CENPF (centromere protein F) and the regulatory Staufen1 RNA-binding protein. SMILR and this downstream axis were also found to be activated in the human ex vivo vein graft pathological model and in primary human coronary artery SMCs and atherosclerotic plaques obtained at carotid endarterectomy. Finally, to assess the therapeutic potential of SMILR, we used a novel siRNA approach in the ex vivo vein graft model (within the 30 minutes clinical time frame that would occur between harvest and implant) to assess the reduction of proliferation by EdU incorporation. SMILR knockdown led to a marked decrease in proliferation from ≈29% in controls to ≈5% with SMILR depletion. CONCLUSIONS Collectively, we demonstrate that SMILR is a critical mediator of vascular SMC proliferation via direct regulation of mitotic progression. Our data further reveal a potential SMILR-targeting intervention to limit atherogenesis and adverse vascular remodeling.
Collapse
MESH Headings
- Cell Cycle/physiology
- Cell Proliferation/physiology
- Cells, Cultured
- Chromosomal Proteins, Non-Histone/genetics
- Chromosomal Proteins, Non-Histone/metabolism
- Humans
- Microfilament Proteins/genetics
- Microfilament Proteins/metabolism
- Mitosis/physiology
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Myocytes, Smooth Muscle/metabolism
- Organ Culture Techniques
- RNA, Long Noncoding/biosynthesis
- RNA, Long Noncoding/genetics
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Saphenous Vein/cytology
- Saphenous Vein/metabolism
- Vascular Remodeling/physiology
Collapse
Affiliation(s)
- Amira D. Mahmoud
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Margaret D. Ballantyne
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Vladislav Miscianinov
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Karine Pinel
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - John Hung
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Jessica P. Scanlon
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Jean Iyinikkel
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Jakub Kaczynski
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Adriana S. Tavares
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Angela C. Bradshaw
- Institute of Cardiovascular and Medical Sciences, BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (A.C.B.)
| | - Nicholas L. Mills
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - David E. Newby
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Andrea Caporali
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Gwyn W. Gould
- Institute of Molecular Cell and Systems Biology, College of Medicine, Veterinary and Life Sciences, University of Glasgow, United Kingdom (G.W.G.)
| | - Sarah J. George
- School of Clinical Sciences, University of Bristol, Research Floor Level Seven, Bristol Royal Infirmary, United Kingdom (S.J.G.)
| | - Igor Ulitsky
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel (I.U.)
| | - Judith C. Sluimer
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
- Department of Pathology, Maastricht University Medical Center, the Netherlands (J.C.S., A.H.B.)
| | - Julie Rodor
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
| | - Andrew H. Baker
- From the Queens Medical Research Institute, BHF Centre for Cardiovascular Sciences, University of Edinburgh, United Kingdom (A.D.M., M.D.B., V.M., K.P., J.H., J.P.S., J.I., J.K., A.S.T., N.L.M., D.E.N., A.C., J.C.S., J.R., A.H.B.)
- Department of Pathology, Maastricht University Medical Center, the Netherlands (J.C.S., A.H.B.)
| |
Collapse
|